| Also known as |
SDX-105 |
| Blood pressure |
Potential for hypertension |
| Chemical name |
4-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid |
| Dosage (medical) |
Typically 100 mg/mВІ on days 1 and 2 of a 28-day cycle, intravenously |
| Dosage (sports) |
Not applicable |
| Effects |
Induces breaks in DNA strands, leading to cell death |
| Formula |
C16H21Cl2N3O2 |
| Half-life |
Approximately 40 minutes |
| Hepatotoxicity |
Mild to moderate potential |
| Lab Test |
Monitoring of blood counts and renal function |
| Main action |
Antineoplastic |
| Side effects |
Myelosuppression, nausea, vomiting, diarrhea, fatigue, fever, anemia |
| Storage conditions |
Store at 25В°C (77В°F), excursions permitted to 15-30В°C (59-86В°F) |
| Substance class |
Alkylating agent |
| Trade name |
Treanda, Bendeka |
| Use in sports |
None |
| Water Retention |
Not typically associated |
| Manufacturer |
Pharmaceutical |
